Merck pilots diabetes SMS campaign in Africa; Pfizer filing for Xeljanz psoriasis approval; Novo teams with MLS club;

> Merck ($MRK) projects a new diabetes SMS campaign in Kenya and Uganda will reach 100,000 people annually. More

> Pfizer ($PFE) by 2015 plans to file for U.S. approval of Xeljanz as a treatment for psoriasis. News

> Sanofi ($SNY) has launched JuniorSTAR, a half-unit insulin reusable pen device that can be used with diabetes giant Lantus. Release

> Major League Soccer club the Philadelphia Union has added Novo Nordisk ($NVO) to its list of corporate partners. More

> Physicians Interactive has launched its Omnio clinical reference application for iPhone and Android. Report

> Pakistan's drug regulatory authority has asked pharma companies to provide details of the doctors and hospitals for which they have provided financial and other benefits. More

> More Pharma has launched Oculus Innovatice Sciences' ($OCLS) Microdacyn60, a treatment for mouth and throat infections, in Mexico. Release

And Finally... With healthcare reform, pharma marketers now have four different groups of targets, each of which requiring its own strategy, Bayer's former marketing VP says. More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.